Pathstone Holdings
AXSM icon

Pathstone Holdings’s Axsome Therapeutics AXSM Stock Holding History

Pathstone Holdings’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Buy
3,408
+24
+0.7% +$5.21K ﹤0.01% 1611
2026
Q1 		$572K Buy
3,384
+107
+3% +$18.5K ﹤0.01% 1689
2025
Q4 		$599K Sell
3,277
-522
-14% -$72.9K ﹤0.01% 1672
2025
Q3 		$461K Buy
3,799
+537
+16% +$60.5K ﹤0.01% 1810
2025
Q2 		$341K Buy
3,262
+10
+0.3% +$1.06K ﹤0.01% 1877
2025
Q1 		$379K Sell
3,252
-254
-7% -$28.9K ﹤0.01% 1845
2024
Q4 		$297K Sell
3,506
-337
-9% -$31K ﹤0.01% 1975
2024
Q3 		$345K Buy
3,843
+76
+2% +$6.63K ﹤0.01% 1911
2024
Q2 		$303K Sell
3,767
-54
-1% -$4K ﹤0.01% 1932
2024
Q1 		$305K Buy
3,821
+172
+5% +$14.4K ﹤0.01% 1940
2023
Q4 		$290K Buy
+3,649
New +$244K ﹤0.01% 1846

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pathstone Holdings's AXSM Position: Q2 2026 in Review

Pathstone Holdings increased its Axsome Therapeutics (AXSM) stake by 0.71% in Q2 2026, buying an estimated $5.21K and bringing the position to 3,408 shares worth $834K. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Pathstone Holdings first reported a position in AXSM in Q4 2023 and has held it in 11 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Pathstone Holdings held 3,408 shares of Axsome Therapeutics worth $834K as of Q2 2026.
  • Pathstone Holdings bought 24 Axsome Therapeutics shares in Q2 2026, an estimated $5.21K.
  • Axsome Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1611 holding.
  • Pathstone Holdings first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.